Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Oncimmune Inks Chinese Licensing Deal for Diagnostics Platform

Oncimmune Inks Chinese Licensing Deal for Diagnostics Platform

Jan 03, 2018
|
staff reporter

NEW YORK (360Dx) – Cancer detection firm Oncimmune announced on Tuesday that it has signed a licensing agreement for its EarlyCDT autoantibody-based diagnostics platform in China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
22
Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

What's Popular?

In Cancer

  1. Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents

  2. OncoLab Diagnostics Targets Cancer Recurrence Monitoring with CTC-Derived Biomarker Assay

    Premium

  3. Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.